The survival benefit of a cardiac resynchronization therapy-defibrillator (CRT-D) lasts for several years in patients with mild-to-moderate symptoms of heart failure (HF), a reduced ejection fraction, ...
Primary analysis of the MADIT-CRT trial demonstrated that male and female patients with NYHA functional class I or II, left ventricular ejection fraction (LVEF) ≤0.30, and QRS duration ≥130 ms are ...
Among patients with nonischemic cardiomyopathy who require cardiac resynchronization therapy, a pacemaker may have comparable efficacy and more cost efficiency compared with a defibrillator, according ...
AMSTERDAM, the Netherlands—Among patients with heart failure with reduced ejection fraction (HFrEF), a previously implanted pacemaker or ICD, and a significant RV pacing burden, upgrading to a cardiac ...
San Francisco, CA - When a heart-failure patient has a defibrillator-equipped cardiac resynchronization therapy (CRT-D) device, antitachycardia pacing (ATP) is preferable to a shock for the treatment ...
Cardiac resynchronization therapy with defibrillator (CRT-D) can help certain patients with non-left bundle branch block (non-LBBB) with heart failure if traditional, implantable cardioverter ...
September 17, 2010 (Natick, Massachusetts) — The FDA is expanding the approved indications for three Boston Scientific cardiac resynchronization defibrillators (CRT-D) to include patients with milder ...
AMSTERDAM -- A cardiac resynchronization therapy (CRT) upgrade produced solid clinical benefit for patients with pacing-induced heart failure with reduced ejection fraction (HFrEF), the small BUDAPEST ...
MILAN, Italy--(BUSINESS WIRE)--Sorin Group (MIL:SRN), (Reuters Code: SORN.MI), a global medical company and a leader in the treatment of cardiovascular diseases, announced today that the INTENSIA ...
Please provide your email address to receive an email when new articles are posted on . Cardiac resynchronization therapy defibrillator implantation conferred improved outcomes vs. implantable ...
Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved ...
Medtronic, Inc. (NYSE: MDT) today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for its cardiac resynchronization therapy with implantable cardioverter ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results